Tag Archives: medical devices

Japanese PE Firm With Over $4B AUM Seeks Novel Life Science Technologies

19 Jul

A private equity firm headquartered in Tokyo, Japan with additional offices throughout USA and Asia. The firm has over $4B AUM and is currently making new investments from three main funds. The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD $3-5 million per round. The firm is currently focused on opportunities in the USA and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm is currently focused on private companies in the US and Japan. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

12 Jul

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Investment Firm with Offices in USA, China, and India Invests Opportunistically in Life Sciences, with Strongest Interest in Novel Medical Devices and Cardiovascular Diseases

28 Jun

Founded in 2015, is a venture capital firm with offices in Boston, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

14 Jun

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Sister Fund to USA-Based Biotech Focused Investment Firm Invests Up to $20M in Therapeutics, Medical Devices with Strong China Angle

14 Jun

A newly established sister fund to a USA based biotech focused fund looks to fund companies either based in China or with a strong China angle. The firm will invest 60-70% of its funds in therapeutics, with the rest in medical devices. For most of its investments, the firm will invest around $20M in Seed to Series A rounds for a majority stake in the company, in addition to taking active part in the company. Occasionally, the firm will make a minority investment in a company, no later than Series B, but is by no means a passive investor. The firm is looking for companies with technologies either in development or in clinical trials, unless based in China, in which case the company’s lead candidate must already be in clinical trials.

While fairly agnostic to subsector and indication, the firm is interested in therapeutics and medical devices that are relevant to the Chinese market. Of particular interest are technologies related to oncology indications common to China, ophthalmic indications, neurodegenerative diseases, and women’s health and fertility.

The firm is looking to take a majority share in most of its portfolio companies, followed by active involvement in company management. In all cases the firm looks to be an active investor. The company must have a China angle, whether it has headquarters or offices there, or is pursuing the Chinese market or clinical trials in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Taiwan Cross Border VC Seeks Medical Devices, Diagnostic Tools, Digital Health, Healthcare IoT Technologies

7 Jun

An early-stage venture capital firm based in Taipei, Taiwan is actively investing in the life sciences space. Formed by a group of successful entrepreneurs, the firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $35 million fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI on MaRS Panel Announcement: Medical Device Investors

22 Mar

By Lucy Parkinson, VP of Investor Research, LSN

Medical device innovation is known for being a challenging area for raising capital.  Given the timelines and capital requirements involved, as well as the increasing consolidation of the major firms that make up the exit landscape for devices, entrepreneurs may find it difficult to build their investment story.  However, LSN is in contact with hundreds of investors who are seeking deals in the device space, either for purely return-driven investments or for adding to a strategic pipeline.  At RESI, we aim to bridge the gap between early stage device firms and investors and help entrepreneurs close those ‘last three feet’ to make deals.

At RESI on MaRS, we welcome a Medical Device Investors panel featuring experienced investors from across North America, including both strategic players and financially-driven venture investors who will explore and elucidate the world of early stage device investment from every angle.  The panel will be moderated by Sam Ifergan, President & CEO, iGan Partners, and the participants are:

  • Katherine Parra Moreno, Vice President of Business Development, Epic Capital Management
  • Zishan Haroon, Chairman and General Partner, Julz Co LLC
  • V Kadir Kadhiresan, Vice President, Venture Investments, Johnson & Johnson Innovation
  • Gerry Brunk, Managing Director, Lumira Capital

%d bloggers like this: